NVL 655
Alternative Names: NUV 655; NVL-655Latest Information Update: 22 May 2024
At a glance
- Originator Nuvalent
- Class Antineoplastics; Small molecules
- Mechanism of Action Anaplastic lymphoma kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Non-small cell lung cancer; Solid tumours
- Preclinical Anaplastic large cell lymphoma; Cholangiocarcinoma; Neuroblastoma; Soft tissue sarcoma
Most Recent Events
- 16 May 2024 NVL 655 receives Breakthrough Therapy status for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA
- 08 Jan 2024 Nuvalent announces intention to submit NDA for NVL 655 in 2026
- 08 Jan 2024 NVL 655 receives Orphan Drug status for Non-small cell lung cancer in USA